<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03965481</url>
  </required_header>
  <id_info>
    <org_study_id>2017-0442</org_study_id>
    <secondary_id>NCI-2019-02455</secondary_id>
    <secondary_id>2017-0442</secondary_id>
    <secondary_id>P30CA016672</secondary_id>
    <nct_id>NCT03965481</nct_id>
  </id_info>
  <brief_title>PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer</brief_title>
  <official_title>Comparing Accuracy of PET/MR vs. CECT in Assessment of Peritoneal Disease for Resectability in Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well positron emission tomography/magnetic resonance (PET/MR) versus
      contrast enhanced computerized tomography (CECT) scans work in locating ovarian cancer tumors
      in patients with known or suspected ovarian cancer. PET, MR, and CECT scans use different
      methods to create images of areas inside the body. This trial is being done to see if PET/MR
      scans may help doctors locate ovarian cancer tumors, predict how well these tumors may be
      removed during surgery, and predict how patients respond to platinum-based chemotherapies
      compared to standard of care CECT scans.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To compare positron emission tomography-magnetic resonance (PET/MR) and contrast enhanced
      computerized tomography (CECT) to determine the accuracy in patients with advanced-stage
      serous ovarian cancer or highly suspected ovarian cancer using diagnostic laparoscopy as the
      gold standard with respect to lesion detection.

      SECONDARY OBJECTIVES (EXPLORATORY):

      I. Correlating imaging findings such as enhancement pattern, apparent diffusion coefficient
      (ADC) values, standardized uptake value (SUV) values, and advanced image analytics such as
      texture with pathology and genomic analysis for those lesions evaluated as a discovery arm.

      II. Assess whether MR (multiparametric and functional) and PET findings predict response to
      platinum based chemotherapy.

      III. To compare PET/MR and contrast enhanced CT to predict tumor negative (R0) resection
      using surgery as the gold standard.

      OUTLINE:

      Patients undergo standard of care CECT scan and PET-MRI scan over 90-120 minutes within 30
      days before laparoscopy or cytoreduction. Patients who do not undergo cytoreduction based on
      diagnostic laparoscopy undergo additional PET-MRI and standard of care CECT scans after
      completion of chemotherapy and before cytoreduction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 12, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lesion detection accuracy</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Lesion detection accuracy will be summarized using frequencies and percentages by modality. McNemar's test will be used to compare accuracies between positron emission tomography (PET)/magnetic resonance (MR) and contrast enhanced computerized tomography (CECT). Other diagnostic metrics (sensitivity, specificity, positive predictive value, and negative predictive value) will be estimated along with 95% confidence intervals. Logistic regression model will be used to assess effect of patient and tumor characteristics on diagnostic accuracy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic accuracy by location</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be analyzed using linear regression or generalized linear regression models where applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response status</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Will be analyzed using linear regression or generalized linear regression models where applicable.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging and genomic data analysis</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Correlation between imaging and genomic data will be analyzed using linear regression or generalized linear regression models where applicable.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Malignant Ovarian Neoplasm</condition>
  <condition>Ovarian Carcinoma</condition>
  <arm_group>
    <arm_group_label>Diagnostic (CECT, PET-MRI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo standard of care CECT scan and PET-MRI scan over 90-120 minutes within 30 days before laparoscopy or cytoreduction. Patients who do not undergo cytoreduction based on diagnostic laparoscopy undergo additional PET-MRI and standard of care CECT scans after completion of chemotherapy and before cytoreduction.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Dynamic Enhanced CT</intervention_name>
    <description>Undergo standard CECT</description>
    <arm_group_label>Diagnostic (CECT, PET-MRI)</arm_group_label>
    <other_name>Contrast-Enhanced Spiral CT</other_name>
    <other_name>Dynamic Contrast Enhanced Computed Tomography</other_name>
    <other_name>Dynamic Contrast Enhanced CT</other_name>
    <other_name>Dynamic Contrast Material Enhanced CT</other_name>
    <other_name>Dynamic Enhanced Computed Tomography</other_name>
    <other_name>Enhanced Spiral CT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Magnetic Resonance Imaging</intervention_name>
    <description>Undergo PET/MRI scan</description>
    <arm_group_label>Diagnostic (CECT, PET-MRI)</arm_group_label>
    <other_name>Magnetic Resonance Imaging Scan</other_name>
    <other_name>Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance</other_name>
    <other_name>MRI</other_name>
    <other_name>MRI Scan</other_name>
    <other_name>NMR Imaging</other_name>
    <other_name>NMRI</other_name>
    <other_name>Nuclear Magnetic Resonance Imaging</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/MRI scan</description>
    <arm_group_label>Diagnostic (CECT, PET-MRI)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ovarian cancer or highly suspected ovarian cancer who are eligible to
             undergo laparoscopic evaluation for resectability will be enrolled in the trial.

          -  Patients who have estimated glomerular filtration rate (eGFR) &gt; 30.

        Exclusion Criteria:

          -  Patients allergic to gadolinium.

          -  Patients who have eGRF &lt; 30.

          -  Patients with cardiac pacers.

          -  Pediatric patients.

          -  Greater than 400 pounds in weight.

          -  Blood glucose (&gt; 200 mg/dl).

          -  Pregnant women.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Priya R Bhosale</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Priya R. Bhosale</last_name>
      <phone>713-792-0221</phone>
      <email>priya.bhosale@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Priya R. Bhosale</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 24, 2019</study_first_submitted>
  <study_first_submitted_qc>May 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2019</study_first_posted>
  <last_update_submitted>June 20, 2020</last_update_submitted>
  <last_update_submitted_qc>June 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

